Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience

被引：1
|
作者：
Nanaa, Ahmad [1 ]
Al-Kali, Aref [1 ]
Viswanatha, David S. [2 ]
Foran, James M. [3 ,4 ]
Badar, Talha [5 ]
Sproat, Lisa Z. [6 ]
He, Rong [7 ]
Nguyen, Phuong L.
Jevremovic, Dragan [2 ]
Salama, Mohamed E. [8 ]
Greipp, Patricia [2 ]
Gangat, Naseema [1 ]
Tefferi, Ayalew [1 ]
Litzow, Mark R. [1 ]
Mangaonkar, Abhishek A. [1 ]
Shah, Mithun V. [1 ]
Patnaik, Mrinal M. [1 ]
Alkhateeb, Hassan B. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA
[4] Mayo Clin, Marrow Transplantat Program, Jacksonville, FL USA
[5] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL USA
[6] Mayo Clin, Div Hematol & Med Oncol, Phoenix, AZ USA
[7] Mayo Clin, Dept Lab Med & Pathol, Div Hematopathol, Rochester, MN USA
[8] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-144400
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3691
引用
收藏
页码：3691 / +
页数：5
相关论文
共 37 条
  • [21] DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia
    Choi, Eun-Ji
    Cho, Young-Uk
    Jang, Seongsoo
    Park, Chan-jeoung
    Park, Han-Seung
    Lee, Jung-Hee
    Lee, Kyoo Hyung
    Hur, Eun-Hye
    Kim, Nayoung
    Ouk, Hee Jeong
    Lee, Je-Hwan
    BLOOD, 2019, 134
  • [22] Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.
    Nanaa, Ahmad
    Alkhateeb, Hassan B.
    Badar, Talha
    Foran, James M.
    Sproat, Lisa Ostrosky
    Yi, Cecilia Ysabel Arana
    Nguyen, Phuong L.
    Jevremovic, Dragan
    Greipp, Patricia T.
    Gangat, Naseema
    Tefferi, Ayalew
    Litzow, Mark Robert
    Shah, Mithun Vinod
    Mangaonkar, Abhishek Avinash
    Patnaik, Mrinal
    Viswanatha, David
    He, Rong
    Al-Kali, Aref
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19010 - E19010
  • [23] DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML
    Quesada, Andres E.
    DiNardo, Courtney
    Routbort, Mark
    Bueso-Ramos, Carlos
    Kanagal-Shamanna, Rashmi
    Zuo, Zhuang
    Yin, C. Cameron
    Loghavi, Sanam
    Ok, Chi Young
    Wang, Sa
    Benton, Christopher
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Medeiros, L. Jeffrey
    Patel, Keyur
    MODERN PATHOLOGY, 2018, 31 : 545 - 545
  • [24] DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML
    Quesada, Andres E.
    DiNardo, Courtney
    Routbort, Mark
    Bueso-Ramos, Carlos
    Kanagal-Shamanna, Rashmi
    Zuo, Zhuang
    Yin, C. Cameron
    Loghavi, Sanam
    Ok, Chi Young
    Wang, Sa
    Benton, Christopher
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    Medeiros, L. Jeffrey
    Patel, Keyur
    LABORATORY INVESTIGATION, 2018, 98 : 545 - 545
  • [25] Peripheral Blood and Bone Marrow Findings in Treatment-Naive Patients With Cytopenia(s)/Myeloid Neoplasms Harboring Both a Germline and a Somatic DDX41 Mutation
    Bruehl, Frido K.
    Younes, Ismail Elbaz
    Bosler, David S.
    Kelemen, Katalin
    Jiang, Liuyan
    Reichard, Kaaren K.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2024, 32 (08) : 371 - 381
  • [26] Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience
    Tessier, Steven
    He, Rong
    Greipp, Patricia
    Viswanatha, David
    Bessonen, Kurt
    Lasho, Terra
    Foran, James
    Arana-Yi, Cecilia
    Gangat, Naseema
    Tefferi, Ayalew
    Shah, Mithun
    Alkhateeb, Hassan
    Liu, Shujun
    Pardanani, Animesh
    Patnaik, Mrinal
    Al-Kali, Aref
    BLOOD ADVANCES, 2024, 8 (18) : 4807 - 4811
  • [27] Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
    Katamesh, Bahga
    Nanaa, Ahmad
    He, Rong
    Viswanatha, David
    Nguyen, Phuong
    Greipp, Patricia
    Bessonen, Kurt
    Gangat, Naseema
    Begna, Kebede
    Mangaonkar, Abhishek
    Patnaik, Mrinal
    Hogan, William J.
    Tefferi, Ayalew
    Litzow, Mark
    Shah, Mithun Vinod
    Yi, Cecilia Arana
    Foran, James
    Badar, Talha
    Alkhateeb, Hassan B.
    Al-Kali, Aref
    BLOOD ADVANCES, 2023, 7 (08) : 1351 - 1355
  • [28] How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms
    Baliakas, Panagiotis
    Tesi, Bianca
    Cammenga, Joerg
    Stray-Pedersen, Asbjorg
    Jahnukainen, Kirsi
    Andersen, Mette Klarskov
    Agerstam, Helena
    Creignou, Maria
    Dybedal, Ingunn
    Raaschou-Jensen, Klas
    Gronbaek, Kirsten
    Kilpivaara, Outi
    Lindberg, Eva Hellstroem
    Wartiovaara-Kautto, Ulla
    HEMASPHERE, 2024, 8 (08):
  • [29] Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
    Alkhateeb, Hassan B.
    Nanaa, Ahmad
    Viswanatha, David
    Foran, James M.
    Badar, Talha
    Sproat, Lisa
    He, Rong
    Nguyen, Phuong
    Jevremovic, Dragan
    Salama, Mohamad E.
    Greipp, Patricia
    Gangat, Naseema
    Tefferi, Ayalew
    Litzow, Mark R.
    Mangaonkar, Abhishek A.
    Shah, Mithun Vinod
    Patnaik, Mrinal
    Al-Kali, Aref
    BLOOD ADVANCES, 2022, 6 (02) : 528 - 532
  • [30] Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
    Kusne, Yael
    Badar, Talha
    Lasho, Terra L.
    Marando, Ludovica
    Mangaonkar, Abhishek A.
    Finke, Christy
    Foran, James M.
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Gangat, Naseema
    Palmer, Jeanne
    Viswanatha, David
    Litzow, Mark R.
    Pardanani, Animesh D.
    Tefferi, Ayalew
    Chlon, Timothy
    Ferrer, Alejandro
    Patnaik, Mrinal M.
    BLOOD, 2024, 144 : 3183 - 3184
1234